Levin Lena-Maria, Völzke Henry, Lerch Markus M, Kühn Jens-Peter, Nauck Matthias, Friedrich Nele, Zylla Stephanie
Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Endocr Connect. 2019 Aug 1;8(8):1097-1107. doi: 10.1530/EC-19-0300.
Chemerin and adiponectin are adipokines assumed to be involved in the development of metabolic syndrome-related phenotypes like hepatic steatosis. We aimed to evaluate the associations of circulating chemerin and adiponectin concentrations with liver enzymes, liver fat content, and hepatic steatosis in the general population.
Data of 3951 subjects from the population-based Study of Health in Pomerania (SHIP-TREND) were used. Hepatic steatosis was assumed when either a hyperechogenic liver (assessed via ultrasound) or a magnetic resonance imaging (MRI)-quantified liver fat content >5% was present. Adjusted sex-specific quantile and logistic regression models were applied to analyze the associations of chemerin and adiponectin with liver enzymes, liver fat content and hepatic steatosis.
The observed associations of chemerin and adiponectin with liver enzymes were very divergent depending on sex, fasting status and the specific enzyme. More consistent results were seen in the analyses of these adipokines in relation to MRI-quantified liver fat content. Here, we observed inverse associations to adiponectin in both sexes as well as a positive (men) or U-shaped (women) association to chemerin. Similarly, the MRI-based definition of hepatic steatosis revealed strongly consistent results: in both sexes, high chemerin concentrations were associated with higher odds of hepatic steatosis, whereas high adiponectin concentrations were associated with lower odds.
Our results suggest a role of these adipokines in the pathogenesis of hepatic steatosis independent of metabolic or inflammatory disorders. However, experimental studies are needed to further clarify the underlying mechanisms and the inter-play between adipokine concentrations and hepatic steatosis.
chemerin和脂联素是被认为参与代谢综合征相关表型（如肝脂肪变性）发展的脂肪因子。我们旨在评估普通人群中循环chemerin和脂联素浓度与肝酶、肝脏脂肪含量及肝脂肪变性之间的关联。
使用了基于人群的波美拉尼亚健康研究（SHIP-TREND）中3951名受试者的数据。当出现肝脏回声增强（通过超声评估）或磁共振成像（MRI）定量肝脏脂肪含量>5%时，判定为肝脂肪变性。应用调整后的性别特异性分位数和逻辑回归模型来分析chemerin和脂联素与肝酶、肝脏脂肪含量及肝脂肪变性之间的关联。
观察到chemerin和脂联素与肝酶的关联因性别、空腹状态及具体酶的不同而差异很大。在分析这些脂肪因子与MRI定量肝脏脂肪含量的关系时，结果更为一致。在此，我们观察到两性中脂联素均呈负相关，而chemerin在男性中呈正相关，在女性中呈U形相关。同样，基于MRI的肝脂肪变性定义显示出高度一致的结果：在两性中，chemerin浓度高与肝脂肪变性的较高几率相关，而脂联素浓度高与较低几率相关。
我们的结果表明这些脂肪因子在肝脂肪变性的发病机制中发挥作用，独立于代谢或炎症紊乱。然而，需要进行实验研究以进一步阐明潜在机制以及脂肪因子浓度与肝脂肪变性之间的相互作用。
